申请人:Aventis Pharma Limited
公开号:US06352977B1
公开(公告)日:2002-03-05
The invention is directed to physiologically active compounds of general formula (I):
wherein R1 is hydrogen, halogen, lower alkyl or lower alkoxy; X1, X2 and X6 independently represent N or CR2; and one of X3, X4 and X5 represents CR3 and the others independently represents N or CR2 where R2 is hydrogen, halogen, lower alkyl or lower alkoxy; and R3 represents a group —L1—(CH2)n—C(═O)—N(R4)—CH2—CH2—Y; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).
该发明涉及一般式(I)的生理活性化合物:
其中R1是氢、卤素、较低的烷基或较低的烷氧基;X1、X2和X6独立地代表N或CR2;其中X3、X4和X5中的一个代表CR3,其他的独立地代表N或CR2,其中R2是氢、卤素、较低的烷基或较低的烷氧基;R3代表一个基团—L1—(CH2)n—C(═O)—N(R4)—CH2—CH2—Y;以及这些化合物及其前药的前药和药学上可接受的盐和溶剂。这些化合物具有有价值的药理特性,特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4(&agr;4&bgr;1)相互作用的能力。